MannKind Corp (NASDAQ:MNKD)

zzlangerhans (99.17) Submitted: 11/20/2008 1:08:18 PM : Start Price: $3.28 MNKD Score: +4.28

I remain long-term negative on Mannkind due to the well-established problems with inhaled insulins. However, the product has solid efficacy data which at least positions it for a favorable review from the FDA. I expect the FDA to set safety standards for Technosphere which are virtually impossible to overcome in terms of time and resources. In the near-to-mid-term I'm positive at this price point.